ArticleFrontiers in pharmacology2025

Case Report: Fluzoparib combined Exemestane in gBRCA2-mutated HR+/HER2- advanced breast cancer.

Dunya Yang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.